Aptevo Therapeutics (NASDAQ:APVO) Issues Earnings Results

Aptevo Therapeutics (NASDAQ:APVO) issued its quarterly earnings data on Thursday. The biotechnology company reported ($2.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.14), Zacks reports.

Aptevo Therapeutics Stock Performance

APVO remained flat at $1.47 on Friday. 1,199,289 shares of the company’s stock traded hands, compared to its average volume of 2,424,141. Aptevo Therapeutics has a 52 week low of $1.32 and a 52 week high of $298.00. The firm’s fifty day simple moving average is $1.55 and its 200-day simple moving average is $3.51. The company has a market capitalization of $4.83 million, a PE ratio of 0.00 and a beta of 5.93.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on APVO shares. Wall Street Zen raised Aptevo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Roth Capital upgraded Aptevo Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 16th. Weiss Ratings reiterated a “sell (e)” rating on shares of Aptevo Therapeutics in a research report on Wednesday. Finally, Zacks Research raised shares of Aptevo Therapeutics to a “hold” rating in a report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Aptevo Therapeutics presently has a consensus rating of “Hold”.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.